HUP0102880A3 - Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions - Google Patents
Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesionsInfo
- Publication number
- HUP0102880A3 HUP0102880A3 HU0102880A HUP0102880A HUP0102880A3 HU P0102880 A3 HUP0102880 A3 HU P0102880A3 HU 0102880 A HU0102880 A HU 0102880A HU P0102880 A HUP0102880 A HU P0102880A HU P0102880 A3 HUP0102880 A3 HU P0102880A3
- Authority
- HU
- Hungary
- Prior art keywords
- coadministration
- acat
- treatment
- atherosclerotic lesions
- mmp inhibitors
- Prior art date
Links
- 229940124761 MMP inhibitor Drugs 0.000 title 1
- 230000003143 atherosclerotic effect Effects 0.000 title 1
- 230000003902 lesion Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Indole Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9363998P | 1998-07-21 | 1998-07-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0102880A2 HUP0102880A2 (en) | 2002-06-29 |
| HUP0102880A3 true HUP0102880A3 (en) | 2002-11-28 |
Family
ID=22239992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0102880A HUP0102880A3 (en) | 1998-07-21 | 1999-06-18 | Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1098662A2 (cs) |
| JP (1) | JP2002521328A (cs) |
| KR (1) | KR20010083134A (cs) |
| CN (1) | CN1310629A (cs) |
| AP (1) | AP2001002035A0 (cs) |
| AU (1) | AU4701799A (cs) |
| BG (1) | BG105162A (cs) |
| BR (1) | BR9912296A (cs) |
| CA (1) | CA2335062A1 (cs) |
| CZ (1) | CZ2001126A3 (cs) |
| EA (1) | EA200100153A1 (cs) |
| EE (1) | EE200100046A (cs) |
| HR (1) | HRP20010055A2 (cs) |
| HU (1) | HUP0102880A3 (cs) |
| ID (1) | ID30030A (cs) |
| IL (1) | IL140982A0 (cs) |
| IS (1) | IS5809A (cs) |
| NO (1) | NO20010291L (cs) |
| OA (1) | OA11584A (cs) |
| PL (1) | PL346011A1 (cs) |
| SK (1) | SK502001A3 (cs) |
| TR (1) | TR200100205T2 (cs) |
| WO (1) | WO2000004892A2 (cs) |
| YU (1) | YU3501A (cs) |
| ZA (1) | ZA200100294B (cs) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003513909A (ja) * | 1999-11-05 | 2003-04-15 | ワーナー−ランバート・カンパニー | Ａｃａｔ阻害剤によるプラーク破裂の予防 |
| GT200000203A (es) | 1999-12-01 | 2002-05-24 | Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas. | |
| JP2003534239A (ja) * | 1999-12-17 | 2003-11-18 | ヴァージコア・インコーポレーテッド | 新規なスクシナート化合物、組成物、並びに使用及び調製方法 |
| RU2246302C2 (ru) * | 2000-09-01 | 2005-02-20 | Санкио Компани, Лимитед | Фармацевтическая композиция для профилактики и лечения нарушений липидного обмена |
| GB0100761D0 (en) | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
| CA2479906C (en) * | 2002-04-03 | 2011-02-08 | Topotarget Uk Limited | Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors |
| CA2492035A1 (en) * | 2002-07-11 | 2004-01-15 | Vicuron Pharmaceuticals, Inc. | N-hydroxyamide derivatives possessing antibacterial activity |
| WO2011092284A1 (en) * | 2010-01-29 | 2011-08-04 | Euroscreen S.A. | Novel amino acid derivatives and their use as gpr43 receptor modulators |
| CN104211695B (zh) * | 2013-06-04 | 2017-04-12 | 中国医学科学院医药生物技术研究所 | 一组胺甲酰基苯磺酰类化合物的用途 |
| US20180000817A1 (en) * | 2015-01-15 | 2018-01-04 | Biocant - Associação De Transferência De Tecnologia | Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing |
| CN106831697B (zh) * | 2017-03-15 | 2019-11-05 | 深圳市康道生物有限公司 | 川榛有效提取成分及其在防治动脉粥样硬化中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5366987A (en) * | 1991-08-22 | 1994-11-22 | Warner-Lambert Company | Isoxazolyl-substituted alkyl amide ACAT inhibitors |
| US5491172A (en) * | 1993-05-14 | 1996-02-13 | Warner-Lambert Company | N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents |
| ES2191762T3 (es) * | 1995-08-04 | 2003-09-16 | Warner Lambert Co | Uso de derivados del acido sulfamico, de acil sulfonamidas o de sulfonil carbamatos para la preparacion de un medicamento para reducir los niveles de lipoproteinas. |
| DE69707865T2 (de) * | 1996-05-17 | 2002-05-02 | Warner-Lambert Co., Morris Plains | Biphenylsulfonamid matrix metalloproteinase inhibitoren |
| NZ333063A (en) * | 1996-09-04 | 2000-12-22 | Warner Lambert Co | Dibenzofuran sulfonamide derivatives as matrix metalloproteinase inhibitors |
-
1999
- 1999-06-18 EA EA200100153A patent/EA200100153A1/ru unknown
- 1999-06-18 EP EP99930483A patent/EP1098662A2/en not_active Withdrawn
- 1999-06-18 SK SK50-2001A patent/SK502001A3/sk unknown
- 1999-06-18 BR BR9912296-0A patent/BR9912296A/pt not_active IP Right Cessation
- 1999-06-18 CN CN99808958A patent/CN1310629A/zh active Pending
- 1999-06-18 IL IL14098299A patent/IL140982A0/xx unknown
- 1999-06-18 EE EEP200100046A patent/EE200100046A/xx unknown
- 1999-06-18 KR KR1020017000930A patent/KR20010083134A/ko not_active Application Discontinuation
- 1999-06-18 ID IDW20010333A patent/ID30030A/id unknown
- 1999-06-18 OA OA1200100022A patent/OA11584A/en unknown
- 1999-06-18 AU AU47017/99A patent/AU4701799A/en not_active Abandoned
- 1999-06-18 AP APAP/P/2001/002035A patent/AP2001002035A0/en unknown
- 1999-06-18 YU YU3501A patent/YU3501A/sh unknown
- 1999-06-18 JP JP2000560885A patent/JP2002521328A/ja active Pending
- 1999-06-18 PL PL99346011A patent/PL346011A1/xx unknown
- 1999-06-18 WO PCT/US1999/013948 patent/WO2000004892A2/en not_active Application Discontinuation
- 1999-06-18 TR TR2001/00205T patent/TR200100205T2/xx unknown
- 1999-06-18 CZ CZ2001126A patent/CZ2001126A3/cs unknown
- 1999-06-18 CA CA002335062A patent/CA2335062A1/en not_active Abandoned
- 1999-06-18 HU HU0102880A patent/HUP0102880A3/hu unknown
-
2001
- 2001-01-10 ZA ZA200100294A patent/ZA200100294B/en unknown
- 2001-01-12 IS IS5809A patent/IS5809A/is unknown
- 2001-01-17 BG BG105162A patent/BG105162A/xx unknown
- 2001-01-18 NO NO20010291A patent/NO20010291L/no not_active Application Discontinuation
- 2001-01-19 HR HR20010055A patent/HRP20010055A2/hr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| SK502001A3 (en) | 2002-06-04 |
| AU4701799A (en) | 2000-02-14 |
| TR200100205T2 (tr) | 2001-05-21 |
| YU3501A (sh) | 2005-06-10 |
| EP1098662A2 (en) | 2001-05-16 |
| BR9912296A (pt) | 2001-04-17 |
| ID30030A (id) | 2001-11-01 |
| NO20010291D0 (no) | 2001-01-18 |
| HRP20010055A2 (en) | 2002-04-30 |
| WO2000004892A2 (en) | 2000-02-03 |
| EA200100153A1 (ru) | 2001-08-27 |
| JP2002521328A (ja) | 2002-07-16 |
| CA2335062A1 (en) | 2000-02-03 |
| NO20010291L (no) | 2001-01-18 |
| CZ2001126A3 (cs) | 2002-01-16 |
| IS5809A (is) | 2001-01-12 |
| OA11584A (en) | 2004-07-20 |
| IL140982A0 (en) | 2002-02-10 |
| EE200100046A (et) | 2002-06-17 |
| HUP0102880A2 (en) | 2002-06-29 |
| ZA200100294B (en) | 2002-01-10 |
| KR20010083134A (ko) | 2001-08-31 |
| CN1310629A (zh) | 2001-08-29 |
| BG105162A (en) | 2001-12-29 |
| PL346011A1 (en) | 2002-01-14 |
| WO2000004892A3 (en) | 2000-05-18 |
| AP2001002035A0 (en) | 2001-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB9800795D0 (en) | Prevention of multiple use of limited use devices | |
| EP1100392A4 (en) | METHODS AND DEVICES FOR REDUCING THE MINERAL CONTENT OF VASCULAR CALCIFIED LESIONS | |
| AU3034300A (en) | Substituted benzimidazoles and their use as parp inhibitors | |
| HUP0101613A3 (en) | Metalloprotease inhibitor (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides and medicaments containing the same | |
| AU2212299A (en) | Compositions and methods for the treatment of tumor | |
| HK1094909A1 (en) | Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis il-18 | |
| HU0900792D0 (en) | Use of renin-angiotensin inhibitors | |
| HU9802971D0 (en) | The use of mmp inhibitors for the treatments of ocular angiogenesis | |
| AU3124300A (en) | Inhibitors of beta-lactamases and uses therefor | |
| GB2342045B (en) | Mineral and vitamin combinations for the treatment of stress and allergies | |
| AU2190400A (en) | Inhibitors of beta-lactamases and uses therefor | |
| PL346011A1 (en) | Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions | |
| HK1041827B (zh) | 用於治療雌激素依賴性疾病的化合物以及製備和使用上述化合物的方法 | |
| HUP0103473A3 (en) | Phosphoglycolipid and methods for its use | |
| EP0964686A4 (en) | METHODS AND COMPOSITIONS FOR PREVENTING OR DELAYING THE DEVELOPMENT OF ATHEROSCLERIC LESIONS | |
| HUP0101947A3 (en) | Combination for the treatment of tumors | |
| NO20004920D0 (no) | Anvendelse av proteaseinhibitorer for behandling av hudskader | |
| IL142471A0 (en) | Fluticasone lotion having improved vasoconstrictor activity | |
| AU7688998A (en) | Use of metalloproteinase inhibitors in the treatment and prevention of pulmonaryemphysema | |
| IL141056A0 (en) | Protease inhibitors for use in the treatment of psoriasis | |
| AU1940800A (en) | Combination therapy for the treatment of sepsis | |
| AU1292000A (en) | Device and method for the direct reduction of iron oxides | |
| EP1135141A4 (en) | PHOSPHOLIPASE INHIBITORS FOR TREATING CANCER | |
| EP1086261A4 (en) | ANTI-CORROSION TREATMENT | |
| GB2343629B (en) | Treatment of cellulite |